Jean-Francois  Formela net worth and biography

Jean-Francois Formela Biography and Net Worth

Jean-François Formela focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.

He is chair of the board of IFM Therapeutics and serves on the boards of F-star, Kyn Therapeutics, Spero Therapeutics, and Translate Bio (formerly RaNA Therapeutics), which he co-founded.

Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Eli Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly). He also was an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).

Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.

Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art.

He received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University.

How do I contact Jean-Francois Formela?

The corporate mailing address for Mr. Formela and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Jean-Francois Formela's contact information.

Has Jean-Francois Formela been buying or selling shares of Intellia Therapeutics?

Jean-Francois Formela has not been actively trading shares of Intellia Therapeutics during the last ninety days. Most recently, Jean Francois Formela sold 553,376 shares of the business's stock in a transaction on Monday, June 28th. The shares were sold at an average price of $132.73, for a transaction totalling $73,449,596.48. Learn More on Jean-Francois Formela's trading history.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company. Learn More about insider trades at Intellia Therapeutics.

Information on this page was last updated on 10/2/2024.

Jean-Francois Formela Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2021Sell553,376$132.73$73,449,596.48View SEC Filing Icon  
6/14/2021Sell170,779$87.37$14,920,961.23View SEC Filing Icon  
6/11/2021Sell30,946$85.23$2,637,527.58View SEC Filing Icon  
4/28/2021Sell131,926$85.56$11,287,588.56View SEC Filing Icon  
4/26/2021Sell806$84.93$68,453.58View SEC Filing Icon  
2/26/2021Sell501,945$60.29$30,262,264.05View SEC Filing Icon  
7/16/2018Sell6,686$31.17$208,402.62View SEC Filing Icon  
6/19/2018Sell6,686$27.96$186,940.56View SEC Filing Icon  
5/16/2018Sell6,686$25.04$167,417.44View SEC Filing Icon  
3/20/2018Sell39,245$23.87$936,778.15View SEC Filing Icon  
3/10/2017Sell21,132$13.91$293,946.12View SEC Filing Icon  
See Full Table

Jean-Francois Formela Buying and Selling Activity at Intellia Therapeutics

This chart shows Jean Francois Formela's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.30
Low: $13.64
High: $14.58

50 Day Range

MA: $18.12
Low: $13.12
High: $22.93

2 Week Range

Now: $14.30
Low: $12.82
High: $34.87

Volume

2,403,759 shs

Average Volume

1,732,812 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81